Bioequivalence and Bioavailability Forum 01:23 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA views on the use of R and other nonproprietary software [Software]

posted by ElMaestro - Denmark, 2017-11-24 19:33  - Posting: # 18002
Views: 787

Hi all,

I stumbled upon this presentation by chance.

The future looks bright for R.

A good weekend to all of you.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,697 posts in 3,982 threads, 1,238 registered users;
online 12 (0 registered, 12 guests [including 10 identified bots]).

Science should always be the basis
of regulatory requirements.    Joachim Röhmel

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed